Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study) (LUNGEVITY)

April 24, 2026 updated by: GFPC Investigation

Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (LUNGEVITY STUDY)

The goal of this observational study is to identify and describe the clinical characteristics, health status, socio-economic impacts and quality of life of patients alive for three years after diagnosis of metastatic Lung cancer and no longer receiving cytotoxic chemotherapy. The main question is to identify the needs of these patients in terms of health status (impact of cancer treatments, incidence of new diseases, cardiovascular, diabetes, second cancers), socio-economic aspects, quality of life and return to employment.

Participants will be asked to answer quality of life questionnaires at the time of inclusion and 6 and 12 months after inclusion and then, every year up to 5 years in this study.

They will be followed regularly, in consultations, according to the usual practices of the physicians in each participating center.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients will be recruited by GFPC centers which is a large French network of hospitals and clinics particularly active in pneumology and thoracic oncology centers participating in clinical research.

The principal investigator in each center will identify consecutive patients eligible for inclusion. Patients will be asked to confirm their consent for data collection.

Description

Inclusion Criteria:

  • Patient over 18 years old
  • Patients alive after more than three years from diagnosis with stage IV or Stage III NSCLC or SCLC, not treated with cytotoxic chemotherapy at the time of inclusion (the patient may be undergoing imunotherapy, targeted therapy or surveillance).
  • Patients covered by the French National Health Insurance program or with thirdparty-payer health insurance

Exclusion Criteria:

  • Difficulties for understanding French
  • Patients undergoing treatment with cytotoxic chemotherapy
  • Patients under legal guardianship, under curatorship or tutorship
  • Insufficient cognitive capacity to answer questions
  • Inability to obtain data collection (lost to follow-up, patient's refusal for data collection)
  • Patients refusing the collection of their data (an information sheet will be provided)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Long-Terms Responders in metastatic Lung Cancer
Long-term responders defined as patients alive for three years after diagnosis of metastatic Lung cancer (NSCLC and SCLC) and not receiving cytotoxic chemotherapy at the time of inclusion.
Behavioral: Hospital Anxiety and Depression scale (HAD)
The HAD scale is an instrument used to screen for anxiety and depressive disorders. It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to depression (total D), giving two scores (maximum score for each = 21).
Behavioral: Quality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13)
The EORTC QLQ-LC13: a 13-item lung cancer-specific questionnaire module supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (cough, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.
Behavioral: Questionnaire Aix-Marseille-Université (AMU)
Data analysis will be firstly descriptive in order to report on the quality of life of respondents. Then, in a second stage, the factors associated with quality of life will be analyzed using linear or logistic regression models depending on the nature of the variable of interest.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Baseline Clinical Characteristics
Time Frame: At Baseline visit, on a maximum period of 12 months.
Metastatic Lung Cancer Long-Terms Responders clinical characteristics: baseline patient demographics, clinical and pathological characteristics (e.g. age, medical history, comorbidities, past history of cancer, smoking status, NSCLC or SCLC characteristics)
At Baseline visit, on a maximum period of 12 months.
Aix-Marseille-University (AMU) questionnaire
Time Frame: At inclusion, 6 and 12 months after inclusion and every year up to 5 years
At inclusion, 6 and 12 months after inclusion and every year up to 5 years
EORTC QLQ-LC13
Time Frame: at inclusion, 6 and 12 months after inclusion and every year up to 5 years
at inclusion, 6 and 12 months after inclusion and every year up to 5 years
Hospital Anxiety and Depression Scale (HAD)
Time Frame: at inclusion, 6 and 12 months after inclusion and every year up to 5 years
at inclusion, 6 and 12 months after inclusion and every year up to 5 years
Treatment characteristics
Time Frame: From date of first lung cancer treatment administration up to 5 years
Treatment characteristics are defined by the type of treatment, the numbers of cycle and the duration of treatment.
From date of first lung cancer treatment administration up to 5 years
Health status
Time Frame: At Baseline visit and up to 5 years
Health status will be evaluated using Eastern Cooperative Oncology Group performance status (PS), and collecting data new diseases, cardiovascular, diabetes, second cancers
At Baseline visit and up to 5 years
Socio-demographic characteristics
Time Frame: At Baseline visit and up to 5 years
Socio-demographic characteristics will be evaluated based on the following data: professional, socio-family and socio-economic characteristics, education, family status, potential professional exposure(s)
At Baseline visit and up to 5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression free survival (PFS)
Time Frame: From date of first lung cancer treatment administration up to 5 years
PFS is defined as the length of time during and after the treatment of cancer, that a patient lives with the disease but it does not get worse. PFS will be assessed by local review, as per the current practice at site.
From date of first lung cancer treatment administration up to 5 years
Overall Survival (OS)
Time Frame: From date of first lung cancer treatment initiation up to 5 years
Overall Survival is defined as the length of time from the start of treatment for the cancer that patients diagnosed with the disease are still alive.
From date of first lung cancer treatment initiation up to 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GFPC Investigation

Investigators

  • Principal Investigator: Lionel FALCHERO, GFPC
  • Principal Investigator: Laurence BIGAY-GAME, GFPC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 2, 2025

Primary Completion (Estimated)

January 31, 2031

Study Completion (Estimated)

January 31, 2031

Study Registration Dates

First Submitted

November 17, 2025

First Submitted That Met QC Criteria

November 17, 2025

First Posted (Actual)

November 21, 2025

Study Record Updates

Last Update Posted (Actual)

April 27, 2026

Last Update Submitted That Met QC Criteria

April 24, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GFPC INVESTIGATION 07-2019

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metastatic Lung Cancer

Clinical Trials on Hospital Anxiety and Depression scale (HAD)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe